From: PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
Variable | Recurrence | RAI refractoriness | Status at last follow-up |
---|---|---|---|
Age | 0.036* | 0.009* | 0.020* |
Sex | 0.696 | 0.147* | 0.051* |
Side of primary tumor | 0.208* | 0.041* | 0.377 |
Histological subtype | 0.039* | 0.029* | <<0.001* |
Vascular invasion | 0.127* | 0.067* | 0.168* |
Status of surgical margins | 0.021* | 0.060* | 0.419 |
T parameter | 0.473 | 0.018* | 0.118* |
N parameter | 0.893 | 0.621 | 0.542 |
M parameter | << 0.001* | << 0.001* | << 0.001* |
Stage | << 0.001* | << 0.001* | << 0.001* |
Administered RAI activity | << 0.001* | << 0.001* | 0.001* |
PSMA positivity | 0.497 | 0.681 | 0.394 |
% PSMA expression | 0.066* | 0.241* | 0.130* |
PSMA 3-point score | 0.451 | 0.917 | 0.680 |
PSMA cumulative score | 0.192* | 0.213* | 0.230* |